Overview

BCG Against Covid-19 for Prevention and Amelioration of Severity Trial (BAC to the PAST)

Status:
Withdrawn

Trial end date:
2022-07-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the efficacy of Bacille Calmette-Guérin (BCG) vaccination compared to placebo in reducing severe Covid-19 disease among elderly residents of skilled nursing facilities. The investigators hypothesize that BCG vaccination can reduce severity of Covid-19 disease. Patients who are residents of participating long-term care facilities (LTCFs), with the ability to understand and cooperate with study procedures, who agree to participate in the study will be randomly assigned to receive BCG vaccination or a placebo. Participants will be followed for up to twelve months to assess severity of Covid-19 outcomes.

Phase:

Phase 3

Details

Lead Sponsor:

Harvard Medical School
Harvard Medical School (HMS and HSDM)

Collaborator:

Texas Medical Research Associates, L.L.C.

Treatments:

BCG Vaccine